Tests Show Eli Lilly's (LLY) Weight-Loss Pill Works as Well as Injection
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The weight-loss pill from Eli Lilly is also equally good at lowering blood sugar levels in people with diabetes, according to new data from a Phase 3 clinical trial. The results were announced at the annual meeting of the American Diabetes Association and the findings published in the prestigious New England Journal of Medicine.
Pharmaceutical giant Eli Lilly currently makes the blockbuster drug Mounjaro for Type 2 diabetes and Zepbound for weight management. Like rival Novo Nordisk's (NVO) Ozempic and Wegovy, both of Eli Lilly's drugs are injected by people on a weekly basis. However, a weight-loss pill is widely viewed as a potential gamechanger given many people's fear of needles and difficulty injecting themselves.
Race for the Pill
Eli Lilly, Novo Nordisk, and other pharmaceutical companies are racing to bring a weight-loss pill to market. Eli Lilly's Orforglipron pill is currently in late stage clinical trials and could be approved by the U.S. Food and Drug Administration (FDA) in 2026, though an exact date is not yet known.
So far, preliminary data on Eli Lilly's pill to help manage obesity is showing promising results. 'What we see is that the efficacy, safety, and tolerability are really consistent with the very best injectable (medications),' said Kenneth Custer, President of Cariometabolic Health at Eli Lilly, in a news release concerning the company's experimental pill. 'We think this is a big deal.'
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy recommendation among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last 12 months. The average LLY price target of $999.57 implies 28.83% upside from current levels.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Growth Accelerates Amid Rising Awareness, Regulatory Approvals, and Strong Pipeline Advancements
The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the market for semaglutide, a GLP-1 receptor agonist, is growing due to its efficacy in glycemic control and weight management. Brand names like Ozempic, Rybelsus, and Wegovy underscore its role in improving health outcomes. Increased awareness, approvals, and advanced delivery systems play pivotal roles in its global adoption. However, challenges like high costs and supply constraints persist. Key players include Novo Nordisk, Eli Lilly, and Pfizer. Semaglutide Market Dublin, July 02, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Semaglutide market will reach US$ 61.7 billion in 2033 from US$ 27.15 billion in 2024 and is anticipated to grow at a CAGR of 9.55% from 2025 to 2033. As the incidence of obesity and type 2 diabetes increases, the efficacy of semaglutide in glycemic control and weight management is driving market demand. Growing awareness, increased approvals, and robust pipeline developments are also driving market growth worldwide. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated mainly for the treatment of type 2 diabetes and chronic weight management. Semaglutide acts similarly to the natural hormone GLP-1, triggering insulin secretion, inhibiting glucagon secretion, and reducing gastric emptying, all of which help to improve blood glucose levels and appetite control. Semaglutide is marketed under brand names like Ozempic, Rybelsus, and Wegovy and is administered by subcutaneous injection or oral tablet, depending on the type 2 diabetes, semaglutide reduces blood sugar levels and decreases the risk of severe cardiovascular events such as heart attack and stroke. In obese and overweight patients with at least one condition related to weight, it facilitates meaningful and durable weight loss when used in addition to lifestyle changes. Semaglutide is attracting widespread interest because of its superior efficacy compared to most other antidiabetic and anti-obesity drugs. Its increased popularity and continued clinical development for new indications indicate a bright future for this of Growth in the Semaglutide Market Inceased Type 2 Diabetes and Obesity PrevalenceIncreased worldwide prevalence of type 2 diabetes and obesity are key drivers for the semaglutide market. Sedentary lifestyles, poor diets, and genetics all play a role in causing these conditions. Semaglutide, a GLP-1 receptor agonist, has proved effective in glycemic control and weight loss, with it being the treatment of choice. With both benefits lying in tackling hyperglycemia and obesity, it results in better patient outcomes and overall quality of life. As diagnosis and awareness improve, demand for such efficient treatments as semaglutide will increase proportionately. In 2022, 2.5 billion adults aged 18 years and above were overweight, of which more than 890 million adults were obese. This is equal to 43% of adults aged 18 years and above (43% of men and 44% of women) who were overweight; up from 1990, when 25% of adults aged 18 years and above were overweight. Overweight prevalence differed by region, ranging from 31% in the WHO South-East Asia Region and the African Region to 67% in the Region of the Expansions and IndicationsSemaglutide's therapeutic applications go beyond diabetes treatment. Its efficacy in weight loss has been demonstrated through clinical trials, and it has been approved for the treatment of obesity under brand names such as Wegovy. Current research extends its applications in reducing cardiovascular risk and other metabolic diseases. Growing approved uses increase the pool of patients for semaglutide treatment, in turn expanding its market. Regulatory approvals and favorable clinical results strengthen clinician confidence and prescribing rates. May 2025, Novo Nordisk reported that the FDA has accepted its New Drug Application for once-daily oral 25 mg formulation of Wegovy (semaglutide) for chronic weight management in adults with obesity or overweight and associated diseases. If approved, it will be the first oral GLP-1 medication for this in Drug Delivery SystemsBreakthroughs in drug delivery have improved semaglutide's availability and patient compliance. The creation of oral forms, like Rybelsus, provides a solution to injectable administration, responding to patient choice and lowering administration hurdles. Enhanced delivery systems add to enhanced compliance, particularly among injection-phobic populations. Such advancements not only enhance patient experience but also grow the market by appealing to new consumers looking for convenient treatment. September 2024, a new delivery system makes it possible to administer semaglutide, which is used in type 2 diabetes and weight management, just once a month rather than weekly. The long-acting form may make it easier for patients to stick with their medication and increase the effectiveness of the drug by keeping levels optimal. The system uses a hydrogel that is composed of two degradable polymers, which slowly releases semaglutide over a month following a single subcutaneous in Semaglutide Market Limited Accessibility and Steep Treatment PricesThe semaglutide treatment may prove to be financially burdensome to most patients, especially in the low- and middle-income bracket. The available insurance cover or high out-of-pocket costs is a hindrance to mass accessibility. Economic barriers influence access, which translates into uneven health consequences. Measures against cost reduction with generic options or subsidies are pivotal to mitigating this challenge so that treatment will be made freely Chain Limitations and Manufacturing ChallengesSatisfying the increasing demand for semaglutide has put manufacturing capacity under pressure, resulting in supply shortages in certain markets. Production intricacies, regulatory challenges, and quality control problems have the potential to upset supply chains. These limitations not only limit drug availability but also influence market expansion and patient confidence. Investment in manufacturing infrastructure and streamlined regulatory processes is needed to address these Semaglutide MarketOzempic, being the once-weekly injectable semaglutide, is mainly used in type 2 diabetes treatment. Its effectiveness in reducing the level of HbA1c as well as inducing weight loss has made it a preferred option among health practitioners. The fact that it is dosed weekly increases patient compliance over daily drugs. Ozempic's popularity has played a crucial role in boosting Novo Nordisk's revenues, which are a clear indication of its dominance in the market. Ongoing marketing initiatives and favorable clinical results underpin its consistent expansion in the diabetes care Semaglutide MarketWegovy, indicated for chronic weight management, is a major breakthrough in the treatment of obesity. Clinical trials have shown significant weight loss among patients treated with Wegovy, which has been approved and widely adopted in the market. Its availability meets the unmet need for effective pharmacologic therapy in obesity, a disease with few treatment options. The success of Wegovy highlights the growing use of semaglutide in the management of metabolic health beyond glucose control. Key Players Analysis: Overview, Key Persons, Recent Development & Strategies, Revenue Analysis Novo Nordisk A/S Eli Lilly and Company AstraZeneca plc Biocon Ltd Johnson and Johnson fizer Inc AbbVie Inc. Sanofi S.A. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $27.15 Billion Forecasted Market Value (USD) by 2033 $61.7 Billion Compound Annual Growth Rate 9.5% Regions Covered Global Key Topics Covered: 1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Semaglutide Market5.1 Historical Market Trends5.2 Market Forecast6. Semaglutide Market Share Analysis6.1 By Product6.2 By Application6.3 By Distribution Channel6.4 By Countries7. Product7.1 Ozempic7.2 Rybelsus7.3 Wegovy7.4 Others8. Application8.1 Type 2 Diabetes8.2 Obesity8.3 Cardiovascular Risk Reduction9. Distribution Channel9.1 Retail Pharmacies9.2 Hospital Pharmacies9.3 Online Pharmacies10. Countries10.1 North America10.1.1 United States10.1.2 Canada10.2 Europe10.2.1 France10.2.2 Germany10.2.3 Italy10.2.4 Spain10.2.5 United Kingdom10.2.6 Belgium10.2.7 Netherlands10.2.8 Turkey10.3 Asia-Pacific10.3.1 China10.3.2 Japan10.3.3 India10.3.4 South Korea10.3.5 Thailand10.3.6 Malaysia10.3.7 Indonesia10.3.8 Australia10.3.9 New Zealand10.4 Latin America10.4.1 Brazil10.4.2 Mexico10.4.3 Argentina10.5 Middle East & Africa10.5.1 Saudi Arabia10.5.2 UAE10.5.3 South Africa11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Semaglutide Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
13 hours ago
- Business Insider
Alpha Cognition shares preclinical data for TBI drug ALPHA-1062
Alpha Cognition (ACOG) announced preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury, or mTBI. The study, supported by the U.S. Department of Defense and conducted with VA investigators, demonstrated that ALPHA-1062 administration following blast-induced mTBI resulted in a notable reduction in indices of TBI-associated neuropathology, including toxic forms of brain protein Tau. These changes suggest a potential role for ALPHA-1062 in treating TBI and possibly reducing the risk of later Alzheimer's disease. Next steps include formulation for sublingual administration and a bridging pharmacokinetic study. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Business Insider
13 hours ago
- Business Insider
Tests Show Eli Lilly's (LLY) Weight-Loss Pill Works as Well as Injection
Preliminary test results show that Eli Lilly's (LLY) daily weight-loss pill, called Orforglipron, is as effective as the company's injectable GLP-1 drug Zepbound. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. The weight-loss pill from Eli Lilly is also equally good at lowering blood sugar levels in people with diabetes, according to new data from a Phase 3 clinical trial. The results were announced at the annual meeting of the American Diabetes Association and the findings published in the prestigious New England Journal of Medicine. Pharmaceutical giant Eli Lilly currently makes the blockbuster drug Mounjaro for Type 2 diabetes and Zepbound for weight management. Like rival Novo Nordisk's (NVO) Ozempic and Wegovy, both of Eli Lilly's drugs are injected by people on a weekly basis. However, a weight-loss pill is widely viewed as a potential gamechanger given many people's fear of needles and difficulty injecting themselves. Race for the Pill Eli Lilly, Novo Nordisk, and other pharmaceutical companies are racing to bring a weight-loss pill to market. Eli Lilly's Orforglipron pill is currently in late stage clinical trials and could be approved by the U.S. Food and Drug Administration (FDA) in 2026, though an exact date is not yet known. So far, preliminary data on Eli Lilly's pill to help manage obesity is showing promising results. 'What we see is that the efficacy, safety, and tolerability are really consistent with the very best injectable (medications),' said Kenneth Custer, President of Cariometabolic Health at Eli Lilly, in a news release concerning the company's experimental pill. 'We think this is a big deal.' Is LLY Stock a Buy? The stock of Eli Lilly has a consensus Strong Buy recommendation among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last 12 months. The average LLY price target of $999.57 implies 28.83% upside from current levels.
